Why this article exists
We have already published the evidence anchor for tesamorelin as our GH-axis lead, and the brief on what the 2026 pooled meta-analysis shows for visceral fat. This piece is the third in that set, and it answers a narrower question: tesamorelin is named in the literature for things other than belly fat — what is the quality of that evidence, and should it change anything?
The honest short answer is that the off-label evidence is uneven. One signal — hepatic fat — is strong enough that it is worth understanding in detail. Another — cognition — is real but rests on a small trial base and a plausible mechanism, not a settled one. And a third "signal" is not clinical at all: it is patient demand, which has risen sharply enough that any physician offering GH-axis therapy will be asked about tesamorelin whether they raise it or not. All three deserve a clear-eyed treatment.
What tesamorelin is, in one paragraph
Tesamorelin is a 44-amino-acid analog of growth-hormone-releasing hormone (GHRH). It binds the pituitary GHRH receptor and stimulates the somatotroph to release growth hormone in the body's own pulsatile pattern — upstream of the pituitary, with the IGF-1 and somatostatin feedback loops left intact. It is the only FDA-approved GHRH analog, approved for the reduction of excess visceral adipose tissue in HIV-associated lipodystrophy. Every use discussed below that sits outside that indication is, by definition, off-label — and we say so on every page that mentions it.
Signal one — hepatic fat. The strongest off-label evidence.
The single most robust effect of tesamorelin outside its labeled visceral-fat indication is on liver fat. In a randomized, double-blind, placebo-controlled trial of adults with HIV and hepatic steatosis, tesamorelin produced an absolute reduction in liver fat fraction and a relative reduction on the order of roughly one-third versus placebo over 12 months, and reduced progression of fibrosis. This was not a body-composition surrogate — it was measured liver fat, with histology in a subset.
Why this matters for a longevity practice: metabolic-dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) is one of the most common and most under-addressed findings in the population Limitless serves — men and women in their 40s through 60s with central adiposity, a borderline metabolic panel, and a fatty liver that no one has named for them. The mechanism by which tesamorelin helps is consistent with everything else known about the GH/IGF-1 axis: restoring pulsatile GH improves hepatic lipid handling. The evidence base is built in an HIV population, and that is a genuine limitation in generalizing it. But it is a Phase-quality randomized signal on a hard endpoint, and it is the reason hepatic fat — not cognition — is the off-label use we actually weigh in clinic.
Signal two — cognition. Real, but not load-bearing.
Tesamorelin's appearance in the cognitive literature is not internet folklore. It rests primarily on a randomized, controlled trial of GHRH administration in older adults — both healthy older adults and adults with mild cognitive impairment (MCI) — in which 20 weeks of GHRH improved performance on executive-function and verbal-memory measures relative to placebo. The compound used was tesamorelin. That is a real, peer-reviewed, placebo-controlled result, and it is why the cognitive endpoint keeps surfacing.
Here is the discipline the result requires. It is one trial, modest in size, with cognitive testing as the endpoint rather than a clinical diagnosis of dementia or its prevention. The mechanism — GH/IGF-1 modulation of hippocampal function and cerebral perfusion — is biologically plausible and supported by separate work, but plausibility is not proof. There is additional, smaller work in HIV-associated neurocognitive disorder, again signal-generating rather than definitive. No regulator anywhere has reviewed tesamorelin for a cognitive indication. The trial base has not been expanded into the large, long, hard-endpoint studies that would move this from "interesting" to "actionable."
So we treat the cognitive data exactly as the GH-axis brief already states: Limitless does not prescribe tesamorelin for a cognitive indication. We mention it because it is true and because patients will encounter it, and a physician who has read the actual trial can give a more useful answer than "I don't know" or an uncritical "yes." If a patient on tesamorelin for a legitimate metabolic indication also reports subjective cognitive benefit, that is consistent with the literature and unsurprising — but it is not the reason the prescription exists.
Signal three — demand. A market fact, handled honestly.
U.S. consumer search interest in tesamorelin grew roughly 49% over six months heading into 2026, into the range of well over one hundred thousand queries a month. That is not a clinical finding and it changes nothing about the evidence. But it is operationally real: it means a meaningful share of new Limitless consultations will include a patient who has already read about tesamorelin, often on a vendor site, and has formed an expectation.
The risk in a demand spike is that clinics meet it by selling the molecule rather than indicating it. Our posture is the opposite. When a patient arrives asking for tesamorelin, the consultation does the same thing it would do for anyone: establish whether there is an indication — visceral adiposity, a body-composition endpoint that has plateaued on training and nutrition, a metabolic or hepatic-fat picture worth addressing — and a baseline IGF-1 and metabolic panel before anything is prescribed. Demand earns a patient a careful evaluation. It does not earn them a prescription.
The evidence, tiered
| Tesamorelin use | Evidence tier | Position at Limitless |
|---|---|---|
| Visceral fat reduction | FDA-approved indication; Phase III | On-label. The core reason tesamorelin is on the menu. |
| Hepatic / liver fat reduction | Randomized controlled trial, hard endpoint | The off-label use we genuinely weigh — in patients with a steatotic-liver and metabolic picture. |
| Skeletal muscle area / density | Secondary-analysis signal | A welcome co-benefit, not a stand-alone indication. |
| Cognition / MCI | Single RCT; plausible mechanism | Not prescribed for this. Discussed honestly when patients ask. |
| General anti-aging / "GH for performance" | Not a recognized indication | Not how we frame or prescribe it. See why we do not prescribe HGH for performance. |
How this changes prescribing — it doesn't
The off-label evidence is noted, not promoted. The prescribing rules are unchanged.
Tesamorelin remains the GH-axis lead for documented visceral adiposity and body-composition endpoints, dosed and monitored exactly as described in the GH-axis brief: baseline IGF-1, A1c, fasting glucose and metabolic panel; 2 mg SubQ evening dosing; 12-week cycles; IGF-1 re-check at 12 weeks with titration or pause above the age-adjusted reference range.
The hepatic-fat evidence strengthens the case for considering tesamorelin in patients who also carry a steatotic-liver and metabolic picture — it does not create a new indication on its own. The cognitive evidence does not change prescribing at all. Demand does not change prescribing at all.
Foundations first, always. The GH axis is layered on top of optimized sleep, training, nutrition, and any indicated hormone optimization — never instead of them.
What we tell every patient
- Tesamorelin is FDA-approved for one specific indication. Everything else — visceral fat outside that population, liver fat, body composition, cognition — is off-label use, supported by literature of varying strength.
- The strongest off-label evidence is for liver fat. The cognitive evidence is real but rests on a single trial; we do not prescribe tesamorelin to improve cognition.
- IGF-1 monitoring is not optional. We pause or titrate above the age-adjusted reference range.
- If you read a vendor page promising "GH-level results" or anti-aging guarantees, that is marketing. The honest version is on this page.
- The peptide compounds the work of training, sleep, and nutrition. It does not replace it.
What updates this article
This article will update if the GHRH cognitive trial base is expanded by a larger or longer study, if the hepatic-fat evidence is extended into a non-HIV MASLD population, after the July 23, 2026 PCAC meeting, and whenever a peer-reviewed paper materially changes the off-label evidence for tesamorelin. The standing posture in the box above governs every Limitless prescription as of 2026-05-23.
The 2026 secondary coverage changes nothing here.
Several consumer-facing 2026 articles have re-summarized the Baker GHRH cognitive RCT — sometimes citing it as a "JAMA Neurology" trial (it was published in Archives of Neurology, which was renamed JAMA Neurology in 2013) — and packaged tesamorelin as a "cognitive longevity" peptide. The underlying evidence base has not changed: it remains one randomized controlled trial of GHRH, modest in size, with cognitive testing as the endpoint. Our prescribing posture is unchanged.
For patients arriving with that question, we have published a brief patient-facing FAQ — Tesamorelin questions, answered honestly — and a parallel internal call script that keeps the answer consistent across the Limitless team.